Co-Authors
This is a "connection" page, showing publications co-authored by Cristina Arriens and Judith James.
Connection Strength
1.497
-
Neutrophils isolated from systemic lupus erythematosus patients exhibit a distinct functional phenotype. Front Immunol. 2024; 15:1339250.
Score: 0.223
-
Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun. 2021; 4:100117.
Score: 0.187
-
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
Score: 0.171
-
Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 04; 7(1).
Score: 0.170
-
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
Score: 0.169
-
Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine. 2020 Mar; 20:100291.
Score: 0.169
-
Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
Score: 0.135
-
Ancestry-based differences in the immune phenotype are associated with lupus activity. JCI Insight. 2023 08 22; 8(16).
Score: 0.054
-
A Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022 Oct 17.
Score: 0.051
-
Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. Front Immunol. 2021; 12:635072.
Score: 0.046
-
Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med. 2019; 6(1):e000365.
Score: 0.042
-
Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken). 2019 11; 71(11):1425-1429.
Score: 0.041
-
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018 Dec 20; 19(1):694.
Score: 0.039